Pharmaceuticals

Pegfilgrastim Biosimilars Market Anticipated to Record Steady Gains, Advancing to $2.65 Billion by 2030

February 18, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the pegfilgrastim biosimilars market from 2026–2035 with trusted insights from The Business Research Company

What total market size is anticipated for the Pegfilgrastim Biosimilars Market in 2030?

The pegfilgrastim biosimilars market has demonstrated robust expansion in its size over recent years. It is projected to increase from $1.92 billion in 2025 to $2.04 billion in 2026, reflecting a compound annual growth rate (CAGR) of 6.3%. This historical growth can be attributed to factors such as the high cost of originator pegfilgrastim, limited availability of biosimilars, an expanding cancer patient population, increasing chemotherapy procedures, and rising awareness of neutropenia management.

The pegfilgrastim biosimilars market is projected to experience robust expansion over the coming years. This market is anticipated to reach $2.65 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.7%. Factors driving this growth during the forecast period include the introduction of novel biosimilars, wider integration into supportive oncology treatments, the expansion of hospital and retail pharmacy distribution channels, governmental encouragement for biosimilar utilization, and increased funding for stem cell transplantation therapies. Key trends expected over the forecast period encompass the growing integration of pegfilgrastim biosimilars in supportive cancer management, the expansion of hospital and retail pharmacy distribution networks, a heightened emphasis on mitigating chemotherapy-induced neutropenia, an increase in hematopoietic and peripheral blood stem cell transplantation applications, and greater financial commitment towards addressing chronic and severe congenital neutropenia.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=4015&type=smp

What Drivers Are Influencing Production Trends In The Pegfilgrastim Biosimilars Market?

Government initiatives promoting the development of biosimilars are projected to propel the pegfilgrastim biosimilars market. Global governments are increasingly prioritizing biosimilar development due to their cost-effectiveness. The US Food and Drug Administration (FDA) launched a Biosimilar Action Plan aimed at increasing available treatment options. Furthermore, the Australian government strengthened its commitment to the Biosimilar Awareness Initiative by granting $5 million to the Generic and Biosimilar Medicines Association to support expanded general biosimilar education and activities that encourage appropriate dispensing, prescription, and utilization of biosimilar medicines. These government initiatives for biosimilar development consequently boost production and awareness, thereby fostering the growth of the pegfilgrastim biosimilars market.

Which Segment Groups Are Influencing The Pegfilgrastim Biosimilars Market?

The pegfilgrastim biosimilars market covered in this report is segmented –

1) By Application: Chemotherapy Treatment, Transplantation, Other Applications

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Mail-Order Pharmacies

3) By Route of Administration: Prefilled Syringes (PFS), On-body Injectors (OBI), Other Routes

Subsegments:

1) By Chemotherapy Treatment: Supportive Care for Cancer Patients, Reduction of Chemotherapy-Induced Neutropenia

2) By Transplantation: Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation

3) By Other Applications: Treatment of Chronic Neutropenia, Treatment of Severe Congenital Neutropenia

What Trends Are Reshaping The Dynamics Of The Pegfilgrastim Biosimilars Market?

Companies active in the pegfilgrastim biosimilars market are concentrating on technological innovation within biopharmaceuticals, specifically creating high-quality biosimilars to offer safe, effective, and accessible alternatives to original biologic therapies for cancer patients. These high-quality biosimilars are biologic drugs that closely resemble the reference product in structure, function, safety, and efficacy. For example, in February 2023, Fresenius Kabi, a Germany-based healthcare company specializing in pharmaceuticals and medical technologies, introduced Stimufend, its initial pegfilgrastim biosimilar in the U.S. Stimufend helps prevent and treat chemotherapy-induced neutropenia and is available as a 6 mg/0.6 mL solution in a single-use pre-filled syringe equipped with a built-in needle guard. By combining advanced biosimilar development with user-friendly delivery, Stimufend represents a technological advancement in improving access to high-quality biologic therapies.

Who Are The Prominent Global Companies Shaping The Pegfilgrastim Biosimilars Market Landscape?

Major companies operating in the pegfilgrastim biosimilars market are Amgen, Mylan N.V., Sandoz (a Novartis division), Teva Pharmaceutical Industries Ltd., Biocon, Pfizer, Celltrion Healthcare, Coherus BioSciences, Gedeon Richter, Fresenius Kabi, Hetero Labs, Intas Pharmaceuticals, LG Chem, Merck KGaA, Zydus Cadila, Aurobindo Pharma, Apotex Inc., Dr. Reddy’s Laboratories, Stada Arzneimittel AG, Shanghai Henlius Biotech, Alvotech, EirGenix, Kye Pharmaceuticals, CinnaGen, Boryung Pharmaceutical, Sinopharm

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/pegfilgrastim-biosimilar-global-market-report

Which Geographic Areas Are Emerging As Strong Markets For The Pegfilgrastim Biosimilars Market?

North America was the largest region in the pegfilgrastim biosimilars market in 2025. Middle East is expected to be the fastest growing region in the global pegfilgrastim biosimilars market share during the forecast period. The regions covered in the pegfilgrastim biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Pegfilgrastim Biosimilars Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=4015&type=smp

Browse Through More Reports Similar to the Global Pegfilgrastim Biosimilars Market 2026, By The Business Research Company

Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Oncology Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/oncology-biosimilar-global-market-report

Oral Biologics And Biosimilars Market 2026

https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilars-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795